N. Nora Bennani, MD, on VSV Therapy and Other Novel Therapies for Lymphoma, Myeloma
The assistant professor at Mayo Clinic School of Medicine discussed plans for further research and a phase 2/3 study.
“The idea is to find targets that will not eliminate all T-cells, and rather, maybe find a target that may eliminate part of the T-cells, but not all, so the patients are still having good immune function to some degree. So that's where I would like to see gene therapy, CAR T-cell therapy heading, is to find additional targets that we can use either for CAR T-cell therapy or oncolytic viral therapy.”
Engineered Vesicular Stomatitis Virus (VSV) therapy may present an alternate mode of novel therapy for treating patients with refractory hematological malignancies in which therapies such as chimeric antigen receptor (CAR) T-cell or gene editing therapies. A phase 1 clinical trial (NCT03017820) being conducted at Mayo Clinic is evaluating VSV-IFNβ-NIS, an engineered VSV therapy in patients with relapsed/refractory multiple myeloma and T-cell lymphoma (TCL).
Study investigator N Nora Bennani, MD, assistant professor, Mayo Clinic College of Medicine, presented the trial design at the
CGTLive® spoke with Bennani to learn more about the potential of VSV therapy and other novel therapies to help address unmet needs in these populations. She shared her group’s efforts to advance the therapy into a phase 2/3 trial if the early trial proves feasible.
REFERENCE
Bennani NN, Cook J, Geyer SM, et al. Phase I trial of systemic administration of vesicular stomatitis virus genetically engineered to express NIS and human interferon, in patients with relapsed or refractory multiple myeloma, lymphomas, or histiocytic/dendritic cell neoplasms. Presented at: ASH 2023 Annual Meeting; December 9-12; San Diego, California. Abstract 5004
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025